Monte Rosa Therapeutics (GLUE) EBT (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly EBT came in at -$44.5 million in Q1 2026, down 193.18% year-on-year from $47.7 million in Q1 2025, and down 51.04% quarter-over-quarter from -$29.4 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) EBT (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$44.5 million for Q1 2026.
- On a quarterly basis, EBT fell 193.18% year-over-year to -$44.5 million in Q1 2026; TTM through Mar 2026 was -$115.2 million, a 1317.87% decrease from a year earlier, with the FY2025 full-year figure at -$23.1 million, up 67.09% from the prior year.
- EBT fell to -$44.5 million in Q1 2026 per GLUE's latest filing, from -$29.4 million in the prior quarter.
- Across five years, EBT topped out at $47.7 million in Q1 2025 and bottomed at -$64.8 million in Q1 2022.
- The 5-year median for EBT is -$30.3 million (2025), against an average of -$24.8 million.
- Across the five-year window, EBT sank 463.48% in 2022 and surged 249.62% in 2025, its largest moves.
- Year by year, EBT stood at -$30.8 million in 2022, then dropped by 8.1% to -$33.3 million in 2023, then surged by 146.89% to $15.6 million in 2024, then plunged by 288.64% to -$29.4 million in 2025, then tumbled by 51.04% to -$44.5 million in 2026.
- Per Business Quant, the three latest GLUE EBT figures stand at -$44.5 million (Q1 2026), -$29.4 million (Q4 2025), and -$30.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -44.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.45 Mn |
| Dec 31, 2025 | -29.43 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -11.10 Mn |
| Mar 31, 2025 | 47.71 Mn |
| Dec 31, 2024 | 15.60 Mn |
| Sep 30, 2024 | -23.79 Mn |
| Jun 30, 2024 | -30.06 Mn |
| Mar 31, 2024 | -31.89 Mn |
| Dec 31, 2023 | -33.27 Mn |
| Sep 30, 2023 | -34.71 Mn |
| Jun 30, 2023 | -34.99 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -64.82 Mn |
| Dec 31, 2021 | -41.16 Mn |
| Sep 30, 2021 | -102.05 Mn |
| Jun 30, 2021 | -102.80 Mn |